Breaking News, Collaborations & Alliances

Charles River, Purespring Collaborate on Gene Therapy Manufacturing

Plasmid CDMO alliance supports first gene therapy platform targeting kidney diseases.

Charles River Laboratories International, and Purespring Therapeutics, a gene therapy company focused on transforming the treatment of kidney diseases, announced a plasmid DNA contract development and manufacturing organization (CDMO) collaboration. Supporting the first gene therapy platform targeting renal diseases, that affect approximately 840 million people, around 10 percent of the global population, the program leverages Charles River’s established plasmid platform, eXpDNA, and decades ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters